Federated Hermes’s Ionis Pharmaceuticals IONS Stock Holding History

Federated Hermes’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-18,473	Closed	-$660K	–	2168
2023 Q1	$660K	Sell	18,473 -8,106	-30%	-$304K	﹤0.01%	1315
2022 Q4	$1M	Buy	26,579 +452	+2%	+$19K	﹤0.01%	1131
2022 Q3	$1.16M	Sell	26,127 -1,110	-4%	-$46.8K	﹤0.01%	1079
2022 Q2	$1.01M	Buy	27,237 +8,875	+48%	+$335K	﹤0.01%	1143
2022 Q1	$680K	Buy	18,362 +14,109	+332%	+$462K	﹤0.01%	1371
2021 Q4	$129K	Hold	4,253	–	–	﹤0.01%	1685
2021 Q3	$143K	Buy	4,253 +163	+4%	+$6.14K	﹤0.01%	1720
2021 Q2	$163K	Buy	+4,090	New	+$160K	﹤0.01%	1713
2021 Q1	–	Sell	-7,622	Closed	-$431K	–	2286
2020 Q4	$431K	Buy	7,622 +18	+0.2%	+$897	﹤0.01%	1551
2020 Q3	$361K	Sell	7,604 -252	-3%	-$14K	﹤0.01%	1555
2020 Q2	$463K	Sell	7,856 -50,379	-87%	-$2.8M	﹤0.01%	1492
2020 Q1	$2.75M	Buy	58,235 +49,217	+546%	+$2.74M	0.01%	798
2019 Q4	$545K	Buy	9,018 +7,299	+425%	+$435K	﹤0.01%	1437
2019 Q3	$103K	Sell	1,719 -129,104	-99%	-$8.41M	﹤0.01%	1658
2019 Q2	$8.41M	Sell	130,823 -137,055	-51%	-$9.69M	0.02%	637
2019 Q1	$21.7M	Buy	267,878 +133,178	+99%	+$8.59M	0.05%	324
2018 Q4	$7.28M	Buy	+134,700	New	+$6.87M	0.02%	621
2017 Q3	–	Sell	-17,664	Closed	-$899K	–	2165
2017 Q2	$899K	Sell	17,664 -44,694	-72%	-$2.08M	﹤0.01%	1243
2017 Q1	$2.51M	Buy	62,358 +42,358	+212%	+$1.9M	0.01%	811
2016 Q4	$957K	Hold	20,000	–	–	﹤0.01%	1150
2016 Q3	$733K	Buy	20,000 +1,034	+5%	+$32.4K	﹤0.01%	1188
2016 Q2	$442K	Buy	+18,966	New	+$612K	﹤0.01%	1307
2016 Q1	–	Sell	-5	Closed	-$1K	–	2132
2015 Q4	$1K	Sell	5 -67,522	-100%	-$3.64M	﹤0.01%	2013
2015 Q3	$2.73M	Buy	67,527 +13,485	+25%	+$698K	0.01%	740
2015 Q2	$3.11M	Buy	54,042 +16,603	+44%	+$1.06M	0.01%	764
2015 Q1	$2.38M	Buy	37,439 +12,773	+52%	+$867K	0.01%	900
2014 Q4	$1.52M	Buy	24,666 +4,358	+21%	+$215K	﹤0.01%	1059
2014 Q3	$789K	Buy	20,308 +5,856	+41%	+$208K	﹤0.01%	1250
2014 Q2	$498K	Sell	14,452 -16,372	-53%	-$516K	﹤0.01%	1352
2014 Q1	$1.33M	Buy	30,824 +8,357	+37%	+$405K	﹤0.01%	1090
2013 Q4	$895K	Sell	22,467 -380	-2%	-$13.5K	﹤0.01%	1190
2013 Q3	$858K	Buy	22,847 +7,059	+45%	+$211K	﹤0.01%	1181
2013 Q2	$424K	Buy	+15,788	New	+$336K	﹤0.01%	1322

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TBC

Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Federated Hermes's IONS Position: Q2 2023 in Review

Federated Hermes sold out of Ionis Pharmaceuticals (IONS) in Q2 2023, closing a stake of 18,473 shares — an estimated $660K sold.

Federated Hermes first reported a position in IONS in Q2 2013 and held it in 33 quarters. The position peaked at $21.7M in Q1 2019. 304 funds tracked by Wall St. Rank hold IONS as of Q2 2023.

Federated Hermes reported no remaining Ionis Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Federated Hermes sold 18,473 Ionis Pharmaceuticals shares in Q2 2023, an estimated $660K.
Federated Hermes first reported a position in Ionis Pharmaceuticals in Q2 2013 and held it in 33 quarters.
Federated Hermes's Ionis Pharmaceuticals position peaked at $21.7M in Q1 2019.
304 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2023.

Based on Federated Hermes's 13F filing for Q2 2023, filed 14 Aug 2023.